Hydroxyapatite microspheres as well as preparation method and application thereof
By preparing monodisperse oil-in-water droplets and adjusting the pH value, the problem of controlling the morphology of hydroxyapatite microspheres was solved, achieving high sphericity and narrow particle size distribution, which is suitable for medical products such as tissue repair, drug carriers and bone fillers.
Patent Information
- Application Number
- CN202512034388.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-30
- Publication Date
- 2026-04-03
AI Technical Summary
Existing technologies struggle to precisely control the microstructure of hydroxyapatite microspheres, making it difficult to achieve high sphericity and narrow particle size distribution.
A method for preparing monodisperse oil-in-water droplets using a dispersed phase and a continuous phase was employed. Ammonia was used to adjust the pH value to induce an aging reaction in the droplets, followed by drying and sintering, to prepare hydroxyapatite microspheres with narrow particle size distribution and high sphericity.
The resulting hydroxyapatite microspheres exhibit narrow particle size distribution, uniform morphology, and high sphericity, making them suitable for applications such as skin soft tissue filling and bone repair.
Smart Images

Figure CN121778684A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of medical device materials technology, and more specifically, to a hydroxyapatite microsphere, its preparation method, and its application. Background Technology
[0002] Hydroxyapatite (HA) is a bioceramic material with a mineral composition similar to that of human bones and teeth. Primarily composed of calcium and phosphate ions, it exhibits excellent biocompatibility, bioactivity, and controllable degradation. In vivo, HA is gradually degraded into calcium and phosphate ions, which participate in physiological metabolic processes without significant inflammation or immune rejection. Therefore, HA is widely used in bone repair, dental materials, and soft tissue filling.
[0003] In recent years, with the rapid development of the medical aesthetics industry, HA microspheres have received much attention as a dermal filler. Compared with traditional cross-linked sodium hyaluronate fillers, HA microspheres can not only provide an immediate filling effect, but also stimulate collagen regeneration and promote tissue regeneration.
[0004] Currently, HA microspheres are mainly prepared through artificial synthesis methods, including solid-phase reaction, mechanical ball milling, chemical precipitation, spray drying, and sol-gel methods. However, these traditional methods have significant drawbacks: the microstructure of HA microspheres is difficult to control precisely, making it difficult to achieve microsphere products with high sphericity and narrow particle size distribution.
[0005] In view of this, the present invention is proposed. Summary of the Invention
[0006] The purpose of this invention is to provide hydroxyapatite microspheres, their preparation method, and their applications, in order to solve or improve the above-mentioned technical problems.
[0007] This invention can be implemented as follows: In a first aspect, the present invention provides hydroxyapatite microspheres, wherein the hydroxyapatite microspheres have a D 10 ≥25μm, D 50 The diameter is 30μm~40μm, D 90 The particle size distribution of the hydroxyapatite microspheres is ≤55μm, and the span value is ≤0.70, while the sphericity is ≥0.92.
[0008] In an optional embodiment, the hydroxyapatite microspheres further include at least one of the following features: Feature 1: The main particle size distribution of hydroxyapatite microspheres is 25μm~55μm; Feature 2: The molar ratio of Ca to P in the hydroxyapatite microspheres is 1.67:1 to 1.72:1; Feature 3: The zeta potential of hydroxyapatite microspheres in 10 mmol / L PBS and phosphate buffer solution at pH 7.4 ranges from -40.5 mV to -26.8 mV. Feature 4: The density of hydroxyapatite microspheres is ≥85%.
[0009] Secondly, the present invention provides a method for preparing hydroxyapatite microspheres as described in the foregoing embodiments, comprising the following steps: preparing a dispersed phase and a continuous phase into monodisperse oil-in-water droplets; adjusting the pH value of the monodisperse oil-in-water droplets with ammonia to induce an aging reaction in the monodisperse oil-in-water droplets, followed by drying to obtain a precursor; removing the oil phase from the precursor and sintering to obtain hydroxyapatite microspheres. The dispersed phase consists of an aqueous phase containing calcium sources, phosphorus sources, and amino acids; the continuous phase consists of an oil phase containing surfactants.
[0010] In an optional implementation, the dispersed phase includes at least one of the following characteristics: Feature 6: The concentration of amino acids in the dispersed phase is 0.02 mol / L to 0.20 mol / L; Feature 7: The amino acids in the dispersed phase include at least one of glutamic acid, aspartic acid, serine, threonine, cysteine, and tyrosine; Feature 8: The concentration of the calcium source in the dispersed phase is 0.1 mol / L to 0.6 mol / L; Feature 9: The calcium source in the dispersed phase includes at least one of calcium nitrate tetrahydrate, calcium hydroxide, and calcium chloride; Feature 10: The molar ratio of phosphorus (P) in the phosphorus source to calcium (Ca) in the calcium source in the dispersed phase is 1:1.67 to 1:1.72; Feature 11: The phosphorus source in the dispersed phase includes at least one of ammonium phosphate, potassium phosphate, and sodium phosphate; Feature 12: The initial pH of the dispersed phase is 7.4 to 8.4.
[0011] In an optional implementation, the continuous phase includes at least one of the following characteristics: Feature 13: The surfactant content in the continuous phase is 2wt%~4wt%; Feature 14: The viscosity of the oil phase in the continuous phase is 50 cSt~100 cSt; Feature 15: The continuous phase is dimethyl silicone oil containing Span 80.
[0012] In an optional implementation, the dispersed phase and the continuous phase are formed into monodisperse oil-in-water droplets using a microfluidic device.
[0013] In an optional embodiment, the preparation of monodisperse oil-in-water droplets includes at least one of the following features: Feature 16: The volumetric flow rate ratio of the dispersed phase to the continuous phase is 0.07:1 to 0.5:1; Feature 17: The flow rate of the dispersed phase is 5 μL / min to 15 μL / min, and the flow rate of the continuous phase is 30 μL / min to 70 μL / min.
[0014] In an optional implementation, the aging reaction includes at least one of the following characteristics: Feature 18: The pH value within the monodisperse oil-in-water droplets is maintained at 9.2~11.0; Feature 19: The flow rate of ammonia is 0.5 L / min to 4 L / min; Feature 20: The aging reaction time is 20 min to 40 min.
[0015] In an optional embodiment, after the aging reaction, the oil phase is separated by centrifugation, followed by washing and drying to obtain the precursor.
[0016] In an optional embodiment, centrifugation is performed at 1000 rpm to 3000 rpm for 5 to 10 minutes. In an optional embodiment, drying is performed at 40°C to 80°C and a vacuum degree of less than 0.1 MPa for 4 to 10 hours.
[0017] In an optional embodiment, the precursor is held at 300°C to 500°C for 30 min to 60 min to remove the oil phase, and then sintered at 600°C to 1100°C for 1 h to 8 h.
[0018] In an optional embodiment, the heating rate during the sintering process is 2°C / min to 5°C / min.
[0019] In an optional embodiment, after sintering, the material is cooled to room temperature at a cooling rate not exceeding 5°C / min.
[0020] Thirdly, the present invention provides the application of hydroxyapatite microspheres as described in the foregoing embodiments in the preparation of medical products.
[0021] In optional embodiments, the medical product includes at least one of tissue repair products, drug carriers, collagen regeneration products, and bone filling products.
[0022] Fourthly, the present invention provides a medical product comprising the hydroxyapatite microspheres of the foregoing embodiments.
[0023] The beneficial effects of this invention include: The hydroxyapatite microspheres provided by this invention have D 10 ≥25μm, D 50 The diameter is 30μm~40μm, D 90The hydroxyapatite microspheres have a particle size distribution of ≤55μm, a span of ≤0.70, and a sphericity of ≥0.92. They exhibit a narrow particle size distribution, uniform morphology, and high sphericity, making them suitable for applications such as skin soft tissue filling and bone repair.
[0024] The preparation method of this hydroxyapatite microsphere includes: preparing a monodisperse oil-in-water droplet from a dispersed phase and a continuous phase; adjusting the pH value of the monodisperse oil-in-water droplet using ammonia to induce an aging reaction in the droplet; drying to obtain a precursor; removing the oil phase from the precursor and sintering. The dispersed phase is an aqueous phase comprising a calcium source, a phosphorus source, and amino acids; the continuous phase is an oil phase comprising a surfactant. This preparation method is simple. By preparing a monodisperse oil-in-water droplet template from the dispersed phase and the continuous phase, combining amino acids as morphology modifiers, and using ammonia curing and high-temperature sintering, the sphericity and particle size distribution of the hydroxyapatite microspheres can be effectively controlled. Attached Figure Description
[0025] To more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings used in the embodiments will be briefly introduced below. It should be understood that the following drawings only show some embodiments of the present invention and should not be regarded as a limitation on the scope. For those skilled in the art, other related drawings can be obtained based on these drawings without creative effort.
[0026] Figure 1 A schematic diagram of the preparation process of hydroxyapatite microspheres provided by the present invention; Figure 2 SEM image of the hydroxyapatite microspheres prepared in Example 1; Figure 3 The infrared absorption spectrum of the hydroxyapatite microspheres prepared in Example 1 is shown below. Figure 4 The image shows the X-ray diffraction pattern of the hydroxyapatite microspheres prepared in Example 1. Detailed Implementation
[0027] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased commercially.
[0028] The following is a detailed description of the hydroxyapatite microspheres provided by this invention, their preparation method, and their applications.
[0029] This invention provides hydroxyapatite microspheres, wherein the hydroxyapatite microspheres have a D 10 ≥25μm, D 50The diameter is 30μm~40μm, D 90 The particle size distribution of the hydroxyapatite microspheres is ≤55μm, and the span value is ≤0.70, while the sphericity is ≥0.92.
[0030] In other words, the hydroxyapatite microspheres provided by this invention have high sphericity, uniform morphology, and narrow particle size distribution.
[0031] In some alternative embodiments, the D of hydroxyapatite microspheres 10 It can be 25μm~30μm, such as 25μm, 27μm or 30μm, or other values in the range of 25μm~30μm.
[0032] D of hydroxyapatite microspheres 50 It can be 30μm, 35μm or 40μm, or other values within the range of 30μm to 40μm.
[0033] D of hydroxyapatite microspheres 90 It can be 45μm~55μm, such as 45μm, 48μm or 55μm, or other values within the range of 45μm~55μm.
[0034] In some optional embodiments, the main particle size distribution of the hydroxyapatite microspheres is 25 μm to 55 μm. Within this particle size range, it also satisfies D... 10 ≥25μm, D 50 The diameter is 30μm~40μm, D 90 ≤55μm.
[0035] In some alternative embodiments, the particle size span of the hydroxyapatite microspheres is 0.60 to 0.68, such as 0.60, 0.63, 0.67 or 0.68, or other values in the range of 0.60 to 0.68.
[0036] In some alternative embodiments, the sphericity of the hydroxyapatite microspheres can be 0.92 to 0.95, such as 0.92, 0.93, 0.94 or 0.95, or other values in the range of 0.92 to 0.95.
[0037] This application satisfies the above-mentioned particle size distribution, D 10 D 50 D 90 Compared with existing hydroxyapatite microspheres, the hydroxyapatite microspheres with improved particle size span and sphericity have a significantly narrower particle size distribution, more regular morphology, and higher sphericity.
[0038] In some alternative embodiments, the molar ratio of Ca to P in the hydroxyapatite microspheres is from 1.67:1 to 1.72:1, such as 1.67, 1.70, or 1.72, or other values within the range of 1.67:1 to 1.72:1. Hydroxyapatite that meets the above Ca:P molar ratio can avoid lattice defects and has better biocompatibility and safety.
[0039] In some alternative embodiments, the zeta potential of the hydroxyapatite microspheres in 10 mmol / L PBS and phosphate buffer solution at pH 7.4 can be from -40.5 mV to -26.8 mV, such as -26.8 mV, -37.6 mV, or -40.2 mV, or other values within the range of -40.5 mV to -26.8 mV. Hydroxyapatite microspheres with the above-mentioned zeta potential exhibit better dispersion stability.
[0040] In some optional embodiments, the density of the hydroxyapatite microspheres is ≥85%, such as 85%~90%, including values like 85%, 88%, or 90%, or other values within the range of 85%~90%. Hydroxyapatite microspheres with the above-mentioned density can possess high mechanical strength, meeting the needs of clinical applications.
[0041] As described above, the hydroxyapatite microspheres provided by this invention have a narrow particle size distribution, regular and uniform microsphere morphology, high sphericity, excellent biocompatibility, good dispersion stability, and moderate mechanical strength.
[0042] The inventors pointed out that the existing technology makes it difficult for hydroxyapatite microspheres to achieve features such as high sphericity and narrow particle size distribution, mainly due to the lack of effective control over the nucleation and growth process, as well as insufficient uniformity of the interface environment.
[0043] Based on this, the present invention creatively provides a method for preparing hydroxyapatite microspheres, such as... Figure 1 As shown, it includes the following steps: Step S1: Prepare monodisperse oil-in-water droplets by combining the dispersed phase and the continuous phase; wherein the dispersed phase is an aqueous phase including a calcium source, a phosphorus source and amino acids; and the continuous phase is an oil phase including a surfactant. Step S2: The pH value inside the monodisperse oil-in-water droplets is adjusted by using ammonia gas to induce an aging reaction in the monodisperse oil-in-water droplets, followed by drying to obtain the precursor; Step S3: Remove the oil phase from the precursor and sinter to obtain hydroxyapatite microspheres.
[0044] This method achieves precise control over the particle size, morphology, and composition of microspheres by preparing a monodisperse oil-in-water droplet template from a dispersed phase and a continuous phase, combining amino acids as morphology modifiers, and using ammonia curing and high-temperature sintering.
[0045] The following is a detailed explanation of each step.
[0046] Step S1: In some alternative embodiments, the dispersed phase and the continuous phase can be formed into monodisperse oil-in-water droplets using a microfluidic device. This microfluidic device provides a micrometer-scale uniform reaction field for droplet formation, ensuring uniform nucleation.
[0047] The aforementioned microfluidic devices are readily available for purchase. For example, they can be fluid focusing chips with channel widths ranging from 50 μm to 300 μm, and can be made of PDMS or glass. In actual operation, the channels can be pre-wetted with a continuous phase (wetting time can be 10 min to 25 min) to reduce surface tension, and the device can be placed in a constant temperature chamber with the temperature controlled at 23℃ to 27℃.
[0048] In some alternative embodiments, the volumetric flow rate ratio of the dispersed phase to the continuous phase can be from 0.07:1 to 0.5:1, such as 0.07:1, 0.1:1, 0.15:1, 0.2:1, 0.25:1, 0.3:1, 0.35:1, 0.4:1, 0.45:1, or 0.5:1, or other values within the range of 0.07:1 to 0.5:1. In some more typical embodiments, the volumetric flow rate ratio of the dispersed phase to the continuous phase can be from 0.16:1 to 0.22:1, and more specifically from 0.167:1 to 0.214:1.
[0049] In some optional embodiments, the flow rate of the dispersed phase can be 5 μL / min to 15 μL / min, such as 5 μL / min, 8 μL / min, 10 μL / min, 12 μL / min or 15 μL / min, or other values within the range of 5 μL / min to 15 μL / min.
[0050] The flow rate of the continuous phase can be from 30 μL / min to 70 μL / min, such as 30 μL / min, 35 μL / min, 40 μL / min, 45 μL / min, 50 μL / min, 55 μL / min, 60 μL / min, 65 μL / min or 70 μL / min, or other values within the range of 30 μL / min to 70 μL / min.
[0051] Both the continuous and dispersed phases can have their flow rates controlled using a precision injection pump. By controlling the volumetric flow rate ratio and velocity of the dispersed and mobile phases, the nucleation state of monodisperse oil-in-water droplets can be effectively controlled. If the volumetric flow rate ratio of the dispersed phase to the continuous phase is less than 0.07:1 (e.g., 0.05:1), it can easily lead to smaller particle sizes; if the volumetric flow rate ratio is greater than 0.5:1 (e.g., 0.6:1), it can easily lead to larger particle sizes and non-uniform droplet sizes.
[0052] In this invention, the amino acids contained in the dispersed phase are selectively adsorbed onto the surface of HA crystals through their functional groups such as carboxyl (-COOH), amino (-NH2), and hydroxyl (-OH), which can regulate the crystal growth rate, inhibit aggregation, and provide electrostatic / steric stability.
[0053] In some alternative embodiments, the amino acids in the dispersed phase may exemplary include at least one selected from glutamic acid, aspartic acid, serine, threonine, cysteine, and tyrosine. These amino acids can occupy growth sites in hydroxyapatite, thereby regulating crystal growth.
[0054] In some optional embodiments, the concentration of amino acids in the dispersed phase can be from 0.02 mol / L to 0.20 mol / L, such as 0.02 mol / L, 0.05 mol / L, 0.1 mol / L, 0.15 mol / L, or 0.2 mol / L, or other values within the range of 0.02 mol / L to 0.20 mol / L. In some more typical embodiments, the concentration of amino acids in the dispersed phase can be from 0.05 mol / L to 0.20 mol / L.
[0055] If the concentration of amino acids in the dispersed phase is too low or too high, it will be detrimental to the growth of hydroxyapatite crystals.
[0056] In some alternative embodiments, the concentration of the calcium source in the dispersed phase can be 0.1 mol / L to 0.6 mol / L, such as 0.1 mol / L, 0.2 mol / L, 0.3 mol / L, 0.4 mol / L, 0.5 mol / L or 0.6 mol / L, or other values within the range of 0.1 mol / L to 0.6 mol / L.
[0057] The calcium source described above may, by way of example, include at least one of calcium nitrate tetrahydrate, calcium hydroxide, and calcium chloride.
[0058] In some alternative embodiments, the molar ratio of phosphorus (P) in the phosphorus source to calcium (Ca) in the calcium source in the dispersed phase can be from 1:1.67 to 1:1.72, such as 1:1.67, 1:1.68, 1:1.69, 1:1.70, 1:1.71 or 1:1.72, or other values within the range of 1:1.67 to 1:1.72.
[0059] The phosphorus source described above may, by way of example, include at least one of ammonium phosphate, potassium phosphate, and sodium phosphate.
[0060] In some alternative embodiments, the initial pH of the dispersed phase can be 7.4 to 8.4, such as 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3 or 8.4, or other values in the range of 7.4 to 8.4.
[0061] In some optional embodiments, the surfactant content in the continuous phase can be 2wt% to 4wt%, such as 2wt%, 2.5wt%, 3wt%, 3.5wt%, or 4wt%, or other values within the range of 2wt% to 4wt%.
[0062] The main function of surfactants in the oil phase is to reduce surface tension and prevent droplet aggregation. Insufficient surfactant will lead to droplet aggregation, while excessive surfactant can cause unstable droplet formation.
[0063] In some optional embodiments, the viscosity of the oil phase in the continuous phase can be 50 cSt to 100 cSt, such as 50 cSt, 60 cSt, 70 cSt, 80 cSt, 90 cSt or 100 cSt, or other values within the range of 50 cSt to 100 cSt.
[0064] In some alternative embodiments, the continuous phase is a dimethyl silicone oil containing Span 80. Additionally, the surfactant may be selected from ABIL EM 90, Pico-Surf, etc. TM The oil phase can also be selected from fluorinated oils and mineral oils, etc.
[0065] In some alternative embodiments, before ammonia is introduced, the obtained monodisperse oil-in-water droplets can be collected in a sealed glass container pre-coated with a surfactant, with a magnetic stir bar (rotation speed of 100 rpm to 200 rpm) placed at the bottom of the container to prevent droplet settling.
[0066] Step S2: In some alternative embodiments, the pH value within the monodisperse oil-in-water droplets is maintained at 9.2–11.0, such as 9.2, 9.5, 9.8, 10, 10.2, 10.5, 10.8, or 11, or other values within the range of 9.2–11.0. In some more typical embodiments, the pH value within the monodisperse oil-in-water droplets is maintained at 10.2–10.8. The pH value within the monodisperse oil-in-water droplets can be tested using a micro pH probe or indicator.
[0067] By introducing ammonia gas, the pH within the monodisperse oil-in-water droplets is rapidly adjusted, thereby promoting the uniform precipitation of calcium phosphate precursors within the droplets. If the pH value within the monodisperse oil-in-water droplets is less than 9.2 (e.g., 9.0), insufficient solidification is likely to occur; if the pH value within the monodisperse oil-in-water droplets is greater than 11.0 (e.g., 11.5), impurity phases are likely to form, thus affecting the purity of the product.
[0068] In some alternative embodiments, the ammonia flow rate can be 0.5 L / min to 4 L / min, such as 0.5 L / min, 1 L / min, 1.5 L / min, 2 L / min, 2.5 L / min, 3 L / min, 3.5 L / min or 4 L / min, or other values within the range of 0.5 L / min to 4 L / min.
[0069] If the flow rate of ammonia is too slow or too fast, it will be difficult to maintain the pH value of monodisperse oil-in-water droplets at 9.2~11.0.
[0070] In some alternative implementations, the aging reaction time can be 20 min to 40 min, such as 20 min, 25 min, 30 min, 35 min or 40 min, or other values within the range of 20 min to 40 min.
[0071] During the aging reaction, the droplets gradually change from transparent to milky white, indicating that the Ca-P complex undergoes uniform nucleation, thus forming the precursor. The aging reaction time affects the precursor particle size; if the aging reaction time is too short, the precursor particle size will be too small; if the aging reaction time is too long, the precursor particle size will be too large.
[0072] After the aging reaction, the oil phase is separated by centrifugation, followed by washing and drying to obtain the precursor.
[0073] In some alternative implementations, centrifugation can be carried out at 1000 rpm to 3000 rpm (e.g., 1000 rpm, 2000 rpm or 3000 rpm) for 5 min to 10 min (e.g., 5 min, 8 min or 10 min).
[0074] In some alternative implementations, washing can be performed using ethanol, and the number of washing cycles can be 3 to 5.
[0075] In some alternative embodiments, drying can be carried out at 40°C to 80°C (e.g., 40°C, 50°C, 60°C, 70°C or 80°C) and a vacuum degree of less than 0.1 MPa for 4h to 10h (e.g., 4h, 6h, 8h or 10h).
[0076] S3 step: In some alternative embodiments, the precursor is held at 300°C to 500°C (e.g., 300°C, 350°C, 400°C, 450°C, or 500°C) for 30 min to 60 min (e.g., 30 min, 40 min, 50 min, or 60 min) to remove the oil phase, and then sintered at 600°C to 1100°C (e.g., 600°C, 700°C, 800°C, 900°C, 1000°C, or 1100°C) for 1 h to 8 h (e.g., 1 h, 2 h, 3 h, 5 h, or 8 h).
[0077] The above sintering process can be carried out in an air atmosphere. The heating rate during the sintering process can be 2℃ / min to 5℃ / min, such as 2℃ / min, 3℃ / min, 4℃ / min or 5℃ / min, or other values within the range of 2℃ / min to 5℃ / min.
[0078] Sintering can improve the densification of hydroxyapatite microspheres.
[0079] In some alternative embodiments, after sintering, the microspheres are cooled to room temperature at a rate not exceeding 5°C / min. For example, the cooling rate can be 5°C / min, 4°C / min, 3°C / min, 2°C / min, or 1°C / min. If the cooling rate is too fast, cracks may easily form in the hydroxyapatite microspheres.
[0080] In addition, the present invention also provides an application of the above-mentioned hydroxyapatite microspheres in the preparation of medical products.
[0081] In some alternative implementations, the medical product may, by way of example but not limitation, include at least one of tissue repair products, drug carriers, collagen regeneration products, and bone filling products.
[0082] Accordingly, the present invention also provides a medical product comprising the above-mentioned hydroxyapatite microspheres.
[0083] Similarly, the medical product may, by way of example but not by way of limitation, include at least one of tissue repair products, drug carriers, collagen regeneration products and bone filling products.
[0084] The features and performance of the present invention will be further described in detail below with reference to embodiments.
[0085] Unless otherwise specified, all raw materials are commercially available analytical grade or medical grade, and the operation is carried out at room temperature (25±2℃) and normal pressure.
[0086] Example 1 This embodiment provides a hydroxyapatite microsphere, the preparation method of which includes: Step S0: Calculate the required amounts based on a Ca:P molar ratio of 1.67. Dissolve analytical grade calcium nitrate tetrahydrate (0.3 mol / L) and diammonium hydrogen phosphate (corresponding molar amounts) in deionized water, maintaining a total volume of 50 mL. Stir at room temperature using a magnetic stirrer for 30 min until completely dissolved and bubble formation avoided. Then, slowly add analytical grade glutamic acid to a final concentration of 0.05 mol / L, continuing stirring for 30 min to promote amino acid-ion complexation. At this point, the initial pH of the dispersed phase is approximately 7.4, requiring no further adjustment.
[0087] For the continuous phase, take analytical grade dimethyl silicone oil with a viscosity of 50 cSt, add Span80 as a surfactant (mass fraction of 2 wt%), and stir at high speed (500 rpm) for 20 min to fully disperse the surfactant and form a stable continuous phase with a total volume of 200 mL.
[0088] Step S1: Using a fluid focusing microfluidic chip (channel width 100μm, material PDMS), the channel was pre-wetted with the continuous phase for 10 min to reduce surface tension. The device was placed in a constant temperature chamber, with the temperature controlled at 25±2℃ and the humidity controlled at <60% to prevent electrostatic interference. A precision syringe pump was used to control the flow rate: the dispersed phase flow rate was 5μL / min, and the continuous phase flow rate was 30μL / min (the volumetric flow rate ratio of dispersed phase to continuous phase Qd / Qc = 0.167:1), forming monodisperse oil-in-water (W / O) droplets.
[0089] Step S2: The generated droplets were collected in a sealed glass container pre-coated with surfactant (volume 100 mL, with a magnetic stir bar at 100 rpm at the bottom to prevent sedimentation). Then, pure ammonia gas was introduced (flow rate 1.6 L / min), and the pH of the droplets was monitored and controlled in real time to 10.8 (verified using a micro pH probe or indicator) to induce an aging reaction in the monodisperse oil-in-water droplets. The aging reaction lasted 30 min, during which the droplets gradually changed from transparent to milky white, indicating initial precipitation of the precursor. After aging, the droplets were centrifuged at 1000 rpm for 5 min, washed three times with ethanol, and then dried under vacuum (40℃, vacuum <0.1 MPa) for 4 h to obtain hydroxyapatite microsphere precursor powder.
[0090] Step S3: Place the hydroxyapatite microsphere precursor powder in a muffle furnace and heat it from room temperature to 300°C at a heating rate of 2°C / min and hold it for 30 min to remove the residual oil phase. Then, heat it from 300°C to 600°C at a heating rate of 2°C / min and hold it for sintering for 5 h. Finally, cool it to room temperature at a cooling rate of 4°C / min.
[0091] Example 2 This embodiment provides a hydroxyapatite microsphere, the preparation method of which includes: S0 Step: Calculate the required amounts based on a Ca:P molar ratio of 1.70. Dissolve analytical grade calcium nitrate tetrahydrate (0.22 mol / L) and dipotassium hydrogen phosphate (corresponding molar amounts) in deionized water, maintaining a total volume of 58 mL. Stir at room temperature using a magnetic stirrer for 45 min until a clear solution is formed. Then, slowly add analytical grade tyrosine to achieve a final concentration of 0.02 mol / L, and continue stirring for 30 min to promote the complexation of amino acids with ions. At this point, the initial pH of the dispersed phase is approximately 8.0, requiring no further adjustment.
[0092] For the continuous phase, take analytical grade dimethyl silicone oil with a viscosity of 60 cSt, add Span80 as a surfactant (mass fraction of 3 wt%), and stir at high speed (900 rpm) for 30 min to fully disperse the surfactant and form a stable continuous phase with a total volume of 300 mL.
[0093] Step S1: Using a fluid focusing microfluidic chip (channel width 100 μm, material PDMS), the channel was pre-wetted with the continuous phase for 15 min to reduce surface tension. The device was placed in a constant temperature chamber, with the temperature controlled at 25±2℃ and the humidity controlled at <60% to prevent electrostatic interference. A precision syringe pump was used to control the flow rate: the dispersed phase flow rate was 10 μL / min, and the continuous phase flow rate was 50 μL / min (the volumetric flow rate ratio of dispersed phase to continuous phase Qd / Qc = 0.20:1), forming monodisperse oil-in-water (W / O) droplets (without satellite droplet generation).
[0094] Step S2: The generated droplets were collected in a sealed glass container pre-coated with surfactant (volume 170 mL, with a magnetic stir bar at 180 rpm at the bottom to prevent sedimentation). Then, pure ammonia gas was introduced (flow rate 0.6 L / min), and the pH of the droplets was monitored and controlled in real time to 9.2 (verified using a micro pH probe or indicator) to induce an aging reaction in the monodisperse oil-in-water droplets. The aging reaction lasted 40 min, during which the droplets gradually changed from transparent to milky white, indicating initial precipitation of the precursor. After aging, the droplets were centrifuged at 1000 rpm for 5 min, washed three times with ethanol, and then dried under vacuum (50℃, vacuum <0.05 MPa) for 6 h to obtain hydroxyapatite microsphere precursor powder.
[0095] Step S3: The hydroxyapatite microsphere precursor powder was placed in a muffle furnace and heated from room temperature to 400°C at a heating rate of 3.5°C / min and held for 45 min to remove the residual oil phase. Then, the temperature was increased from 400°C to 900°C at a heating rate of 3.5°C / min and held for sintering for 3 h. Finally, the temperature was cooled to room temperature at a cooling rate of 3°C / min.
[0096] Example 3 This embodiment provides a hydroxyapatite microsphere, the preparation method of which includes: Step S0: Calculate the required amounts based on a Ca:P molar ratio of 1.72. Dissolve analytical grade calcium nitrate tetrahydrate (0.4 mol / L) and disodium hydrogen phosphate (corresponding molar amounts) in deionized water, maintaining a total volume of 65 mL. Stir at room temperature using a magnetic stirrer for 60 min until completely dissolved and bubble formation avoided. Then, slowly add analytical grade serine to a final concentration of 0.2 mol / L, continuing stirring for 40 min to ensure uniform distribution. At this point, the initial pH of the dispersed phase is approximately 8.3, requiring no further adjustment.
[0097] For the continuous phase, take analytical grade dimethyl silicone oil with a viscosity of 70 cSt, add Span80 as a surfactant (mass fraction of 3.5 wt%), and stir at high speed (1200 rpm) for 45 min to fully disperse the surfactant and form a stable continuous phase with a total volume of 500 mL.
[0098] Step S1: A fluid focusing microfluidic chip (channel width 100 μm, material PDMS) was used. The channel was pre-wetted with the continuous phase for 20 min to reduce surface tension. The device was placed in a constant temperature chamber, and the temperature was controlled at 25 ± 2 °C. A precision syringe pump was used to control the flow rate: the dispersed phase flow rate was 15 μL / min, and the continuous phase flow rate was 70 μL / min (the volumetric flow rate ratio of the dispersed phase to the continuous phase Qd / Qc = 0.214:1), forming monodisperse oil-in-water (W / O) droplets.
[0099] Step S2: The generated droplets were collected in a sealed glass container (230 mL) pre-coated with surfactant. A magnetic stir bar (260 rpm) was placed at the bottom of the container to prevent sedimentation. Then, pure ammonia gas (flow rate 2.5 L / min) was introduced, and the pH of the droplets was monitored and controlled in real time to 10.6 (verified using a micro pH probe or indicator) to induce an aging reaction in the monodisperse oil-in-water droplets. The aging reaction lasted 20 min. During the aging reaction, the droplets gradually changed from transparent to milky white, indicating initial precipitation of the precursor. After the aging reaction, the droplets were centrifuged at 1000 rpm for 5 min, washed three times with ethanol, and then dried under vacuum (60 °C, vacuum <0.01 MPa) for 7 h to obtain hydroxyapatite microsphere precursor powder.
[0100] Step S3: Place the hydroxyapatite microsphere precursor powder in a muffle furnace and heat it from room temperature to 500°C at a heating rate of 5°C / min and hold it for 60 min to remove the residual oil phase. Then, heat it from 500°C to 1100°C at a heating rate of 5°C / min and hold it for sintering for 4 h. Finally, cool it to room temperature at a cooling rate of 1°C / min.
[0101] Example 4 This embodiment provides a hydroxyapatite microsphere, the preparation method of which includes: Step S0: Calculate the required amounts based on a Ca:P molar ratio of 1.69. Dissolve analytical grade calcium chloride (concentration range 0.5 mol / L) and disodium hydrogen phosphate (corresponding molar amount) in deionized water, with a total volume controlled at 70 mL. Stir at room temperature using a magnetic stirrer for 60 min until completely dissolved and bubble formation is avoided. Then, slowly add analytical grade threonine to achieve a final concentration of 0.15 mol / L, and continue stirring for 40 min to ensure uniform distribution. At this point, the initial pH of the dispersed phase is approximately 8.2, requiring no further adjustment.
[0102] For the continuous phase, take analytical grade mineral oil with a viscosity of 60 cSt, add ABIL EM 90 as a surfactant (mass fraction of 4 wt%), and stir at high speed (900 rpm) for 40 min to fully disperse the surfactant and form a stable continuous phase with a total volume of 350 mL.
[0103] Step S1: Using a fluid focusing microfluidic chip (channel width 100 μm, material PDMS), the channel was pre-wetted with the continuous phase for 15 min to reduce surface tension. The device was placed in a constant temperature chamber, with the temperature controlled at 25±2℃ and the humidity controlled at <60% to prevent electrostatic interference. A precision syringe pump was used to control the flow rate: the dispersed phase flow rate was 5 μL / min, and the continuous phase flow rate was 70 μL / min (the volumetric flow rate ratio of dispersed phase to continuous phase Qd / Qc = 0.07:1), forming monodisperse oil-in-water (W / O) droplets (without satellite droplet generation).
[0104] Step S2: The generated droplets were collected in a sealed glass container (260 mL) pre-coated with surfactant. A magnetic stir bar (300 rpm) was placed at the bottom of the container to prevent sedimentation. Then, pure ammonia gas (4 L / min) was introduced, and the pH of the droplets was monitored and controlled to 11 (verified using a micro pH probe or indicator) to induce an aging reaction in the monodisperse oil-in-water droplets. The aging reaction lasted 25 min. During the aging reaction, the droplets gradually changed from transparent to milky white, indicating initial precipitation of the precursor. After the aging reaction, the droplets were centrifuged at 1000 rpm for 5 min, washed three times with ethanol, and then dried under vacuum (60 °C, vacuum <0.01 MPa) for 7 h to obtain hydroxyapatite microsphere precursor powder.
[0105] Step S3: The hydroxyapatite microsphere precursor powder is placed in a muffle furnace and heated from room temperature to 450°C at a heating rate of 5°C / min and held for 50 min to remove the residual oil phase. Then, the temperature is increased from 450°C to 1050°C at a heating rate of 5°C / min and held for sintering for 6 h. Finally, the temperature is cooled to room temperature at a cooling rate of 4°C / min.
[0106] Comparative Example 1 The difference between this comparative example and Example 1 is that no amino acids were used in the preparation process, and the initial pH of the dispersed phase was 9.7.
[0107] Comparative Example 2 The difference between this comparative example and Example 1 is that the concentration of amino acids in the dispersed phase is 0.5 mol / L.
[0108] Comparative Example 3 The difference between this comparative example and Example 1 is that the amino acid used is histidine.
[0109] Comparative Example 4 The difference between this comparative example and Example 1 is that the volumetric flow rate ratio of the dispersed phase to the continuous phase is 0.02:1.
[0110] Comparative Example 5 The difference between this comparative example and Example 1 is that the volumetric flow rate ratio of the dispersed phase to the continuous phase is 0.7:1.
[0111] Comparative Example 6 The difference between this comparative example and Example 1 is that the monodisperse oil-in-water (W / O) droplets were not prepared using a microfluidic device, but were prepared directly using conventional mixing methods in the art.
[0112] Test case The performance of the hydroxyapatite microspheres prepared in Examples 1-4 and Comparative Examples 1-6 was tested, and the results are shown in Table 1. Figures 2 to 4 As shown.
[0113] Among them, particle size distribution (D 10 D 50 D 90 The particle size distribution was determined using a laser particle size analyzer or image analysis method; sphericity was calculated statistically from SEM images (based on statistics of 100 microspheres); span is the intra-batch particle size span value; zeta potential was determined in 10 mmol / L PBS and phosphate buffer at pH 7.4; density was determined by the water displacement method; the Ca:P molar ratio was determined by inductively coupled plasma optical emission spectroscopy (ICP-OES); XRD was used for phase identification, confirming it as hydroxyapatite phase (no specific peak intensity ratio requirement).
[0114] Table 1 Test Results
[0115] Table 1 shows that the hydroxyapatite microspheres prepared in Examples 1-4 have uniform composition and meet biocompatibility requirements; narrow particle size distribution with no obvious multi-peaks; SEM observation shows that the microspheres are regular spheres with smooth surfaces and high sphericity; the particle size span is small, indicating good batch-to-batch repeatability. Suitable surface charge indicates good dispersion stability; high density, low internal porosity, and good mechanical properties. XRD patterns show characteristic peaks matching those of standard hydroxyapatite, with no impurity phase peaks.
[0116] In contrast, the hydroxyapatite microspheres prepared in Comparative Example 1 showed significant shoulder peaks and a larger particle size span; the microspheres were clearly elliptical, with approximately 18% of the particles being concave; and the density was relatively low.
[0117] This demonstrates that although HA microspheres can be obtained without the addition of amino acids, the particle size distribution is broadened, the particle size span is increased, the sphericity is reduced, and the density is decreased. Compared with Example 1, this confirms that amino acids play a regulatory role in the entire process of crystal nucleation, growth, and densification within microfluidic oil droplets.
[0118] Furthermore, as can be seen from Comparative Examples 2-6, under conditions of changing amino acid concentration, amino acid type, continuous phase / dispersed phase flow rate volume ratio, and without using a microfluidic device, the prepared hydroxyapatite microspheres have a wider particle size distribution, lower sphericity, and reduced density, confirming that the above conditions have a regulatory effect on the entire process of crystal nucleation-growth-densification.
[0119] In summary, the preparation method of hydroxyapatite microspheres provided by this invention is simple and can effectively control the sphericity and particle size distribution of the hydroxyapatite microspheres. The resulting product has advantages such as high sphericity, uniform morphology, narrow particle size distribution, high density, and good stability, and is suitable for applications such as skin soft tissue filling and bone repair.
[0120] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.
Claims
1. A hydroxyapatite microsphere, characterized in that, The D of the hydroxyapatite microspheres 10 ≥25μm, D 50 The diameter is 30μm~40μm, D 90 The particle size distribution is ≤55μm, and the particle size span of the hydroxyapatite microspheres is ≤0.70, and the sphericity is ≥0.
92.
2. The hydroxyapatite microspheres according to claim 1, characterized in that, The hydroxyapatite microspheres also include at least one of the following characteristics: Feature 1: The main particle size distribution of the hydroxyapatite microspheres is 25μm~55μm; Feature 2: The molar ratio of Ca to P in the hydroxyapatite microspheres is 1.67:1 to 1.72:1; Feature 3: The hydroxyapatite microspheres exhibit a zeta potential of -40.5 mV to -26.8 mV in 10 mmol / L PBS and phosphate buffer solution at pH 7.
4. Feature 4: The density of the hydroxyapatite microspheres is ≥85%.
3. A method for preparing hydroxyapatite microspheres as described in claim 1 or 2, characterized in that, Includes the following steps: The dispersed phase and the continuous phase were prepared into monodisperse oil-in-water droplets; the pH value of the monodisperse oil-in-water droplets was adjusted by ammonia gas to induce an aging reaction in the monodisperse oil-in-water droplets, followed by drying to obtain a precursor; the oil phase in the precursor was removed and sintered to obtain the hydroxyapatite microspheres. The dispersed phase is an aqueous phase comprising a calcium source, a phosphorus source, and amino acids; the continuous phase is an oil phase comprising a surfactant.
4. The preparation method according to claim 3, characterized in that, The dispersed phase includes at least one of the following characteristics: Feature 6: The concentration of amino acids in the dispersed phase is 0.02 mol / L to 0.20 mol / L; Feature 7: The amino acids in the dispersed phase include at least one of glutamic acid, aspartic acid, serine, threonine, cysteine, and tyrosine; Feature 8: The concentration of the calcium source in the dispersed phase is 0.1 mol / L to 0.6 mol / L; Feature 9: The calcium source in the dispersed phase includes at least one of calcium nitrate tetrahydrate, calcium hydroxide, and calcium chloride; Feature 10: The molar ratio of phosphorus (P) in the phosphorus source to calcium (Ca) in the calcium source in the dispersed phase is 1:1.67 to 1:1.72; Feature 11: The phosphorus source in the dispersed phase includes at least one of ammonium phosphate, potassium phosphate, and sodium phosphate; Feature 12: The initial pH value of the dispersed phase is 7.4~8.
4.
5. The preparation method according to claim 3, characterized in that, The continuous phase includes at least one of the following characteristics: Feature 13: The surfactant content in the continuous phase is 2wt%~4wt%; Feature 14: The viscosity of the oil phase in the continuous phase is 50 cSt~100 cSt; Feature 15: The continuous phase is dimethyl silicone oil containing Span 80.
6. The preparation method according to any one of claims 3 to 5, characterized in that, The dispersed phase and the continuous phase are formed into monodisperse oil-in-water droplets by a microfluidic device; Preferably, the preparation of monodisperse oil-in-water droplets includes at least one of the following characteristics: Feature 16: The volumetric flow rate ratio of the dispersed phase to the continuous phase is 0.07:1 to 0.5:1; Feature 17: The flow rate of the dispersed phase is 5 μL / min to 15 μL / min, and the flow rate of the continuous phase is 30 μL / min to 70 μL / min.
7. The preparation method according to claim 3, characterized in that, Aging reactions include at least one of the following characteristics: Feature 18: The pH value within the monodisperse oil-in-water droplets is maintained at 9.2~11.0; Feature 19: The flow rate of the ammonia gas is 0.5 L / min to 4 L / min; feature 20: The aging reaction time is 20 min to 40 min; Preferably, after the aging reaction, the oil phase is separated by centrifugation, followed by washing and drying to obtain the precursor; preferably, centrifugation is performed at 1000 rpm to 3000 rpm for 5 min to 10 min. Preferably, the drying is carried out at 40℃~80℃ and under a vacuum of less than 0.1MPa for 4h~10h.
8. The preparation method according to claim 3, characterized in that, The precursor was held at 300℃~500℃ for 30min~60min to remove the oil phase, and then sintered at 600℃~1100℃ for 1h~8h. Preferably, the heating rate during the sintering process is 2℃ / min to 5℃ / min; Preferably, after sintering, the sample is cooled to room temperature at a cooling rate not exceeding 5°C / min.
9. The use of hydroxyapatite microspheres as described in claim 1 or 2 in the preparation of medical products; Preferably, the medical product includes at least one of tissue repair products, drug carriers, collagen regeneration products, and bone filling products.
10. A medical product, characterized in that, Includes the hydroxyapatite microspheres as described in claim 1 or 2.
